Ulcerative Colitis in Adults: Diagnosis and Management
Diagnosis
The diagnosis of ulcerative colitis requires clinical presentation combined with endoscopic evaluation and histologic confirmation, after excluding infectious and other etiologies. 1
Clinical Assessment
- Disease severity classification uses the Truelove and Witts criteria: severe UC is defined as bloody stool frequency ≥6/day plus at least one of: tachycardia (>90/min), fever (>37.8°C), anemia (hemoglobin <10.5 g/dL), or elevated ESR (>30 mm/h) or CRP (>30 mg/L) 2
- Disease extent must be determined by endoscopy: proctitis (rectum only), left-sided (up to splenic flexure), or extensive (beyond splenic flexure) 2
- Patients meeting severe criteria require immediate hospital admission to prevent increased perioperative morbidity and mortality 2
Endoscopic Evaluation
- Colonoscopy with biopsies is the gold standard for diagnosis and should assess disease extent and severity 1
- Characteristic findings include continuous, confluent colonic involvement with clear demarcation and rectal involvement 2
- Flexible sigmoidoscopy is sufficient for confirming severe colitis and excluding infection; full colonoscopy is not recommended in acute severe UC, particularly in patients on corticosteroids 2
- Endoscopic severity features include hemorrhagic mucosa with deep ulceration, mucosal detachment, and well-like ulceration 2
Laboratory and Imaging
- At admission for severe colitis: obtain complete blood count, CRP or ESR, electrolytes, liver function tests, stool culture, and C. difficile toxin assay 2
- Plain abdominal radiograph should be performed to exclude colonic dilatation (≥5.5 cm), estimate disease extent, and identify poor prognostic features (mucosal islands, >2 gas-filled small bowel loops) 2
- Infection, particularly CMV, must be excluded with urgent histopathology if strongly suspected 2
Management Strategy by Disease Severity and Extent
Mild-to-Moderate Proctitis
Mesalamine 1g suppository once daily is the preferred initial treatment for mild-to-moderate proctitis 2
- Suppositories deliver drug more effectively to the rectum and are better tolerated than foam or enemas 2
- Topical mesalamine is superior to topical corticosteroids (pooled OR 8.3 for symptomatic remission, 5.3 for endoscopic remission) 2
- Combination therapy (topical mesalamine plus oral mesalamine 2-4g daily) is more effective than monotherapy 2
- Refractory proctitis requires systemic steroids, immunosuppressants, or biologics 2
Mild-to-Moderate Left-Sided or Extensive Disease
Oral mesalamine 2-4g daily or balsalazide 6.75g daily are first-line therapy for mild-to-moderately active disease 2
- For distal disease, combine topical mesalamine 1g daily with oral mesalamine for optimal efficacy 2
- Prednisolone 40mg daily is appropriate when prompt response is required or when mesalamine fails 2
- Taper prednisolone gradually over 8 weeks; more rapid reduction increases early relapse risk 2
- Olsalazine 1.5-3g daily has higher diarrhea incidence in pancolitis; reserve for left-sided disease or mesalamine intolerance 2
Severe Ulcerative Colitis
Severe UC requires joint management by gastroenterology and colorectal surgery with immediate hospital admission 2
Acute Management Protocol
- Intravenous corticosteroids (hydrocortisone 400mg/day or methylprednisolone 60mg/day) are the initial treatment 2
- Monitor vital signs four times daily, maintain stool chart, and obtain daily labs (CBC, CRP/ESR, electrolytes, albumin) 2
- Daily abdominal radiography if colonic dilatation detected at presentation; low threshold for repeat imaging if clinical deterioration 2
- Provide IV fluid/electrolyte replacement, blood transfusion to maintain hemoglobin >10 g/dL, and subcutaneous heparin for thromboembolism prophylaxis 2
- Nutritional support (enteral or parenteral) if malnourished 2
- Inform patients of 25-30% colectomy risk 2
Moderate-to-Severe Disease: Advanced Therapies
For moderate-to-severe UC, the AGA recommends infliximab, golimumab, vedolizumab, tofacitinib, upadacitinib, ustekinumab, ozanimod, etrasimod, risankizumab, and guselkumab over no treatment (strong recommendation, moderate-to-high certainty evidence) 2
First-Line Biologic Selection (Biologic-Naïve Patients)
In biologic-naïve patients, use infliximab or vedolizumab rather than adalimumab for induction of remission 2
- Vedolizumab demonstrated superior clinical remission versus adalimumab in head-to-head trial (34.2% vs 24.3%; RR 1.41) 2
- Patients valuing convenience of self-administered subcutaneous injection may reasonably choose adalimumab 2
- JAK inhibitors have restricted use: FDA recommends use only after TNF antagonist failure or intolerance in the United States 2
- European Medicine Agency recommends cautious first-line JAK inhibitor use in patients ≥65 years, current/previous smokers, or those with cardiovascular disease or cancer history 2
Dosing Considerations
- Tofacitinib induction: 10mg twice daily for 8 weeks; may extend to 16 weeks in select cases with modest response 2
- Tofacitinib maintenance: 5mg twice daily for most patients; higher doses carry increased risk of pulmonary embolism and all-cause mortality 2
- Extended induction regimens (up to 16 weeks) or dose escalation may benefit patients with severe disease 2
- Biosimilars of infliximab, adalimumab, and ustekinumab are equivalent to originator drugs 2
- Subcutaneous formulations of infliximab and vedolizumab show comparable efficacy to IV maintenance 2
Immunomodulator Therapy
Thiopurines and Methotrexate
The AGA suggests against using thiopurine monotherapy for inducing remission in active disease (conditional recommendation, very low certainty) 2
- Thiopurine monotherapy may be used for maintaining remission typically induced with corticosteroids (conditional recommendation, low certainty) 2
- Methotrexate monotherapy is not recommended for inducing or maintaining remission (conditional recommendation, low certainty) 2
- Azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day are appropriate for steroid-dependent disease 2
Combination Therapy
Combine TNF antagonists with immunomodulators rather than TNF antagonist monotherapy (conditional recommendation, low-to-moderate certainty) 2
- No recommendation exists for combining non-TNF biologics with immunomodulators versus monotherapy (knowledge gap) 2
Maintenance Therapy and De-escalation
Long-Term Maintenance
Lifelong maintenance therapy is generally recommended for all patients, especially those with left-sided or extensive disease, and those with distal disease relapsing more than once yearly 2
- Maintenance therapy with aminosalicylates, azathioprine, or mercaptopurine reduces relapse risk 2
- Maintenance therapy may reduce colorectal cancer risk 2
- Discontinuation may be reasonable for distal disease patients in remission for 2 years who are averse to medication 2
De-escalation Strategy
In patients who failed 5-aminosalicylates and escalated to immunomodulators or advanced therapies, stop 5-aminosalicylates (conditional recommendation, low certainty) 2
In patients achieving corticosteroid-free clinical remission for ≥6 months on TNF antagonist plus immunomodulator combination therapy, do not withdraw TNF antagonists (conditional recommendation, very low certainty) 2
- No recommendation exists for withdrawing immunomodulators or continuing combination therapy (knowledge gap) 2
Special Considerations
Steroid-Refractory Disease
- Ciclosporin may be effective for severe, steroid-refractory colitis 2
- Consider colectomy in refractory cases or presence of high-grade epithelial dysplasia 3
Monitoring and Surveillance
- Mucosal healing is the primary treatment goal and should be confirmed endoscopically 3
- Mucosal healing after 1 year associates with low colectomy risk (1.6% vs 7% without healing) 2
- Regular surveillance colonoscopies for colorectal cancer should be scheduled at risk-stratified intervals 3